PepGen

Q2 FY2026 EarningsQ2 FY2026 results for PEPG beat consensus estimates on the bottom line, with a GAAP EPS of -$0.26 vs. -$0.29 expected. As a clinical-stage biotech, revenue remained at zero, in line with expectations. The net loss of $17.8M was narrower than the anticipated $20.2B, primarily driven by reduced R&D spending following the discontinuation of the DMD program in May 2025. Management confirmed a cash runway into Q4 2027, providing a stable liquidity buffer for the ongoing Phase 2 FREEDOM2 study.